Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CR1N | ISIN: KYG1996C1006 | Ticker-Symbol:
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
CARSGEN THERAPEUTICS HOLDINGS LTD Chart 1 Jahr
5-Tage-Chart
CARSGEN THERAPEUTICS HOLDINGS LTD 5-Tage-Chart

Aktuelle News zur CARSGEN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR SATRICABTAGENE AUTOLEUCEL ...2
MiUBS Raises TPs for CSPC PHARMA/CARSGEN-B to HKD10/HKD3211
16.06.CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS ON CT071 AT 2025 EHA ANNUAL CONGRESS3
02.06.CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS ON SATRI-CEL IN THE LANCET AND AT THE 2025 ASCO ANNUAL MEETING1
28.05.CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SATRICABTAGENE AUTOLEUCEL GRANTED PRIORITY REVIEW BY THE NMPA1
CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln
22.05.CARSGEN-B (02171): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 MAY 2025-
13.05.CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY2
12.05.CARsgen Therapeutics: CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy393SHANGHAI, May 11, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies...
► Artikel lesen
29.04.CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON CT071 ACCEPTED FOR POSTER PRESENTATION AT 2025 EHA ANNUAL CONGRESS1
16.04.CARSGEN-B (02171): GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME; AND GRANT OF RSUS PURSUANT TO THE POST-IPO RSU SCHEME1
16.04.CARSGEN-B (02171): LETTER TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS-
16.04.CARSGEN-B (02171): LETTER TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS-
16.04.CARSGEN-B (02171): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING2
16.04.CARSGEN-B (02171): NOTICE OF ANNUAL GENERAL MEETING1
16.04.CARSGEN-B (02171): PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITOR ...-
16.04.CARSGEN-B (02171): ANNUAL REPORT 2024-
27.03.CARsgen's R&D Progress Should Be A Key Watchpoint For Investors1
27.03.CARsgen seeks cell therapy breakthrough but stays in the red for now2
19.03.CARsgen Therapeutics: CARsgen Announced 2024 Annual Results469SHANGHAI, March 18, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced its...
► Artikel lesen
18.03.CARSGEN-B (02171): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024-
Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1